Cemiplimab or Cemiplimab and Fianlimab After Stereotactic Body Radiotherapy in Clear Cell Renal Cell Carcinoma

Authors
Category Primary study
Registry of TrialsClinicalTrials.gov
Year 2025
The purpose of this research is to test the safety of PD-1 inhibitor cemiplimab with or without LAG-3 inhibitor fianlimab, and see what effects (good and bad) of cemiplimab either alone or combined with fianlimab has on patients with oligometastatic clear cell renal cell carcinoma after completion of radiation therapy.
Epistemonikos ID: 7ba12a03e1d1491ea9e095ad87f548b3ee95fbce
First added on: Nov 04, 2025